Member Info for Bothwell

For China, yes, the reference product is Senstend, which is the marketing name for Fortacin - it’s the exact same product, just a different name for China. Therefore, it follows that the CMC documentation is exactly the same whether its Senstend or Fortacin so its completely wrong to say no CMC data exists. Genetic has the CMC data, including stability data for China which is 30 °C/65% RH at various time points starting at release, 3 months, 6 months, etc... And no MHRA authorisation has not expired – regulatory consultant filed in February 2024 with MHRA for the first 5-yearly renewal application for Senstend to MHRA. This should result in the GB MA being renewed for a period of unlimited validity (no further application would be required in a further 5 years).

Is my friend correct or incorrect?

And simply no the assumptions aren’t correct.

For example, the CMC data is not missing - if it was how could Genetic be approved by both MHRA and EMA as an alternative manufacturer? Also, the US phase II results and the phase III results in China as previously announced were successful in meeting their primary and co primary end points. Further, supply is not an issue…

Sorry just in response to our friend.

What was the name of the disgruntled employee?

I dont’t. Been assured there is a Money Fountain on its way!

Wow Dougie! 6 years and you don’t think we will get China nor USA!

Has Dr Mike left the ship???

Hope you are correct Stretch.

Will we see a re-rate in the SP that they spoke about, get the product to market in China and USA before I require my pension in 6 years……

Regent Pacific Group Ltd on Tuesday said it has agreed to acquire the shares it doesn't already own in Plethora Solutions Holdings PLC, valuing the premature ejaculation treatment company at 11.65 pence per share.

The deal values Plethora at about GBP95.9 million, based on the number of shares in issue, and at GBP114.3 million when considering its fully diluted share capital. Shareholders in Plethora will receive 15.7076 new Regent Pacific shares for each Plethora share they own. Shares in Plethora jumped by 18% to 5.30p on Tuesday afternoon.

Not when you have been here since it was in the pennies.

On the 10th March 2016 Regent Pacific Group Limited (“Regent Pacific” or “the Group”; stock code: 00575) is pleased to announce today that it has successfully completed the acquisition of London AIM listed Plethora Solutions Holdings Plc

Well 8 years since this day, so much has gone wrong and the SP has been decimated. Jamie wage packet has pocketed him millions since then for not producing any results…. A product that is required by so many men but we can’t get it to market in China or the USA.

Sad to see my investment dwindle to an all time low and no sign of it recovering soon due to dilution.

The money fountain hasn’t begun to flow…..

Written off my six figure investment.

Is WK the only asset ready to be sold immediately. What are the realistic value of the others ready to be sold to China!

How much is WK worth to us?

Morning Bignose, thank you for getting in contact with the BoD and asking the correct questions. It really is a shambles that China isn’t further on and the US is not closer to completion. Can believe JM is just paying Jamie to do nothing. Dr Mike seems to have vanished off the scene. Dilution was a terrible for us private holders but good for the BoD. 2025 has now move to 2026. I finally have no confidence in the BOD had my investment has gone.

As I said a year or so ago, I have a feeling that 2025 is the year we will see the approval in the US complete and possibly a China at the beginning of 2025. Jim Mellon isn’t investing his millions in here to keep Jamie living he could just move him to another of his companies.

Why the 17% jump today.

I think if Bignose or Italian asked some of their questions to Jim Mellon he would respond. The journey continues.

Maybe time to email Jim Mellon with your thoughts Bignose?

I have sent him a couple of emails but no response from him. Usually very good.